Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.71 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677018 | 0.93 | GRM5 (0.61) | GRM5CES2ADRB2HTR6TP53 | |
| SCHEMBL3832229 | 0.92 | GRM5 (0.60) | GRM5CES2TP53 | |
| SCHEMBL13677021 | 0.91 | GRM5 (0.70) | GRM5CES2HTR2AHTR6 | |
| SCHEMBL13677020 | 0.91 | GRM5 (0.66) | GRM5CES2HTR1AHTR2AHTR7 | |
| SCHEMBL13677017 | 0.90 | GRM5 (0.65) | GRM5CES2ADRB2 | |
| SCHEMBL3831773 | 0.89 | CES2 (0.62) | GRM5CES2ADRB2ALDH1A1HPGD | |
| SCHEMBL3835283 | 0.89 | GRM5 (0.59) | GRM5CES2HTR1AHTR2AHTR7 | |
| SCHEMBL3836518 | 0.89 | GRM5 (0.57) | GRM5CES2HTR1AHTR2AHTR7 | |
| SCHEMBL13677022 | 0.88 | GRM5 (0.56) | GRM5CES2 | |
| SCHEMBL13677015 | 0.88 | GRM5 (0.60) | GRM5CES2HTR1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | GRM5 1/4885CES2 791/4885ADRB2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.